The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.

Company Guidance -

Q3 2025

During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key metrics. They announced the completion of end-of-Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, and their preparation to initiate a pivotal Phase II trial in the second half of 2025. Additionally, the NatHaLi-01 study on UCART20x22 is progressing, with Phase I data anticipated by late 2025. Cellectis is advancing three cell and gene therapy programs under their partnership with AstraZeneca. Financially, the company reported cash, cash equivalents, and fixed-term deposits of $230 million as of June 30, 2025, which are expected to fund operations into the second half of 2027. They are also involved in arbitration with Servier, with a decision expected by December 15, 2025. The company will provide further insights and data during their Investor R&D Day on October 16, 2025.

Initiation of Pivotal Phase II Trial for lasme-cel

Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.

Ongoing R&D Partnership with AstraZeneca

Research and development activities continue under the collaboration with AstraZeneca, focusing on three cell and gene therapy programs, including CAR-T for hematological malignancies, CAR-T for solid tumors, and in vivo gene therapy for a genetic disorder.

Strong Financial Position

Cellectis' cash, cash equivalents, and fixed-term deposits as of June 30, 2025, amount to $230 million, sufficient to fund operations into H2 2027.

Upcoming Investor R&D Day

Cellectis will host an Investor R&D Day on October 16, 2025, to present Phase I data and late-stage development strategy for lasme-cel.

Cellectis SA (FR:ALCLS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FR:ALCLS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.20 / -	-0.211	―	―	―
Aug 04, 2025	2025 (Q2)	-0.19 / -0.21	-0.256	18.75% (+0.05)	―
May 12, 2025	2025 (Q1)	-0.14 / -0.16	0.074	-317.57% (-0.23)	―	―
Mar 13, 2025	2024 (Q4)	-0.17 / -0.16	-0.599	73.96% (+0.44)	―
Nov 04, 2024	2024 (Q3)	-0.22 / -0.21	-0.29	27.24% (+0.08)	―
Aug 06, 2024	2024 (Q2)	-0.26 / -0.26	-0.172	-48.84% (-0.08)	―	―
May 28, 2024	2024 (Q1)	-0.31 / 0.07	-0.527	114.04% (+0.60)	―
Mar 11, 2024	2023 (Q4)	-0.26 / -0.07	-0.558	86.56% (+0.48)	―	―
Nov 06, 2023	2023 (Q3)	-0.39 / -0.29	-0.637	54.47% (+0.35)	―
Aug 03, 2023	2023 (Q2)	-0.40 / -0.17	-0.413	58.35% (+0.24)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FR:ALCLS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	€2.75	€2.33	-15.12%
May 12, 2025	€1.35	€1.33	-1.33%
Mar 13, 2025	€1.25	€1.22	-1.92%
Nov 04, 2024	€1.73	€1.70	-1.51%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cellectis SA (FR:ALCLS) report earnings?

Cellectis SA (FR:ALCLS) is schdueled to report earning on Nov 10, 2025, TBA (Confirmed).

What is Cellectis SA (FR:ALCLS) earnings time?

Cellectis SA (FR:ALCLS) earnings time is at Nov 10, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Cellectis SA stock?

The P/E ratio of Cellectis SA is N/A.

What is FR:ALCLS EPS forecast?

FR:ALCLS EPS forecast for the fiscal quarter 2025 (Q3) is -0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing